27
Views
2
CrossRef citations to date
0
Altmetric
Review

Pharmacoeconomic review of recombinant human DNase in the management of cystic fibrosis

, , &
Pages 49-59 | Published online: 09 Jan 2014
 

Abstract

For the treatment of patients with cystic fibrosis, recombinant human deoxyribonuclease I is widely used. Deoxyribonuclease I has a positive effect on lung function and the number of hospitalizations. Deoxyribonuclease I is currently administered by nebulization, which is an inefficient administration method. For expensive drugs, such as deoxyribonuclease I, dry powder inhalation would be advantageous due to increased deposition efficiency, patient mobility and compliance. Furthermore, a significant cost reduction may be obtained. The current status of deoxyribonuclease I in the management of cystic fibrosis was investigated and special attention given to the developments in delivery systems, such as dry powder inhalation. It is estimated that if dry powder inhalation of deoxyribonuclease I could be used, a reduction in the cost-effectiveness ratio of approximately 40% can be obtained as compared with nebulization.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.